| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 50mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Antibody-drug conjugate (ADC) linker - cleavable linker for ADC synthesis.
|
|---|---|
| ln Vitro |
In vitro studies on Fmoc-Phe-Lys(Trt)-PAB-PNP are limited, as the compound is primarily used as a chemical intermediate for ADC synthesis rather than as a pharmacological agent. The compound's role is as a linker that connects the antibody to the cytotoxic payload in ADCs. The PAB (para-aminobenzyl) group provides a self-immolative spacer that enables controlled release of the payload upon cleavage. The Lys(Trt) group provides a protected lysine residue for further conjugation, and the Fmoc group enables solid-phase peptide synthesis. The compound's utility is in the synthesis of ADCs rather than in direct biological assays.
|
| ln Vivo |
In vivo studies on Fmoc-Phe-Lys(Trt)-PAB-PNP are not applicable, as the compound is a chemical intermediate used for ADC synthesis and is not administered as a therapeutic agent itself. The compound is used in the production of ADCs, which are then evaluated in vivo for their antitumor efficacy and safety. The linker's properties, such as stability in circulation and controlled release of the payload, are critical for ADC performance, but these are evaluated at the ADC level rather than for the linker alone.
|
| Enzyme Assay |
For ADC synthesis, Fmoc-Phe-Lys(Trt)-PAB-PNP is used as a building block in solid-phase peptide synthesis (SPPS). The Fmoc group is removed by treatment with piperidine, allowing for the sequential addition of amino acids. The Trt (trityl) group on the lysine side chain is removed under acidic conditions, enabling further conjugation. The PAB-PNP (para-aminobenzyl-p-nitrophenyl carbonate) group serves as a self-immolative spacer and a handle for conjugation to the cytotoxic payload. The compound's purity and identity are confirmed by HPLC, NMR, and mass spectrometry.
|
| Cell Assay |
Cellular assays are not directly applicable to Fmoc-Phe-Lys(Trt)-PAB-PNP, as the compound is a chemical intermediate for ADC synthesis rather than a pharmacological agent. The ADCs synthesized using this linker are evaluated in cellular assays for target binding, internalization, and cytotoxicity. Cytotoxicity is assessed using cell viability assays (MTT or CellTiter-Glo) on target antigen-expressing cancer cell lines. The linker's ability to release the payload in a controlled manner is evaluated by measuring payload release in cell lysates or conditioned media.
|
| Animal Protocol |
In vivo studies are not directly applicable to Fmoc-Phe-Lys(Trt)-PAB-PNP, as the compound is a chemical intermediate for ADC synthesis. ADCs synthesized using this linker are evaluated in animal models of cancer for antitumor efficacy and safety. Tumor-bearing mice are treated with the ADC, and tumor volume is monitored over time. Pharmacokinetic studies are conducted to determine the ADC's half-life, clearance, and tissue distribution. The linker's stability in circulation and controlled release of the payload are critical for ADC performance and are evaluated at the ADC level.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties are not directly applicable to Fmoc-Phe-Lys(Trt)-PAB-PNP, as the compound is a chemical intermediate for ADC synthesis rather than a therapeutic agent. The ADCs synthesized using this linker are characterized for their pharmacokinetic properties, including half-life, clearance, volume of distribution, and bioavailability. The linker's properties, such as stability in circulation and susceptibility to cleavage, influence the pharmacokinetics of the ADC. These properties are determined using LC-MS/MS analysis of plasma and tissue samples following ADC administration.
|
| Toxicity/Toxicokinetics |
Toxicological evaluation is not directly applicable to Fmoc-Phe-Lys(Trt)-PAB-PNP, as the compound is a chemical intermediate for ADC synthesis rather than a therapeutic agent. The ADCs synthesized using this linker are evaluated for their safety and toxicity in preclinical studies. Standard toxicology assessments include acute and repeated-dose toxicity studies in rodents and non-rodent species, evaluation of off-target toxicity, and histopathological examination of major organs. The linker's properties, such as stability and payload release, influence the ADC's toxicity profile.
|
| Additional Infomation |
Fmoc-Phe-Lys(Trt)-PAB-PNP is a cleavable linker designed specifically for antibody-drug conjugate (ADC) synthesis. The compound is a fully protected dipeptide linker intermediate that contains an Fmoc group for solid-phase peptide synthesis, a Trt-protected lysine for conjugation, and a PAB-PNP self-immolative spacer for payload release. The compound is used as a key building block for the synthesis of ADCs, which are targeted cancer therapies that combine the specificity of monoclonal antibodies with the potency of cytotoxic drugs. Fmoc-Phe-Lys(Trt)-PAB-PNP is not a drug and is not intended for therapeutic use; its primary application is as a chemical intermediate in ADC research and development.
|
| Molecular Formula |
C63H57N5O9
|
|---|---|
| Molecular Weight |
1028.15479636192
|
| Exact Mass |
1027.415
|
| CAS # |
1116086-09-9
|
| PubChem CID |
118798952
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
11.9
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
24
|
| Heavy Atom Count |
77
|
| Complexity |
1790
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
C1=CC=C(C=C1)C[C@@H](C(=O)N(C2=CC=C(C=C2)COC(=O)OC3=CC=C(C=C3)[N+](=O)[O-])[C@@H](CCCCNC(C4=CC=CC=C4)(C5=CC=CC=C5)C6=CC=CC=C6)C(=O)N)NC(=O)OCC7C8=CC=CC=C8C9=CC=CC=C79
|
| InChi Key |
LOGURWMJSNXIEZ-YQOHNZFASA-N
|
| InChi Code |
InChI=1S/C63H57N5O9/c64-59(69)58(31-17-18-40-65-63(46-21-7-2-8-22-46,47-23-9-3-10-24-47)48-25-11-4-12-26-48)67(49-34-32-45(33-35-49)42-76-62(72)77-51-38-36-50(37-39-51)68(73)74)60(70)57(41-44-19-5-1-6-20-44)66-61(71)75-43-56-54-29-15-13-27-52(54)53-28-14-16-30-55(53)56/h1-16,19-30,32-39,56-58,65H,17-18,31,40-43H2,(H2,64,69)(H,66,71)/t57-,58-/m0/s1
|
| Chemical Name |
[4-[[(2S)-1-amino-1-oxo-6-(tritylamino)hexan-2-yl]-[(2S)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-3-phenylpropanoyl]amino]phenyl]methyl (4-nitrophenyl) carbonate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.9726 mL | 4.8631 mL | 9.7261 mL | |
| 5 mM | 0.1945 mL | 0.9726 mL | 1.9452 mL | |
| 10 mM | 0.0973 mL | 0.4863 mL | 0.9726 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
